Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.

Biotech 2010-Life Sciences:
Adapting for Success
Individual Chapters

Now Available for Purchase
Individual Chapters of
Biotech 2010-Life Sciences:
Adapting for Success
in PDF Format

Charles Darwin told us that it is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change. Biotech 2010—Life Sciences: Adapting for Success, Burrill & Company’s latest annual report on the industry, provides insight into biotech’s changing environment and how not to just survive but succeed.
The publication provides thoughtful information and analysis on how companies need to adapt to major challenges to their business development in order to be successful in 2010 and beyond. These include: raising capital, impending healthcare reform, comparative effectiveness research, generics, biosimilars, reimbursement pressures and regulatory changes.
In addition Biotech 2010 presents:
• Comprehensive 2009 industry financials, private and public capital raised, M&A/Partnering activity of life sciences companies operating in the United States, Europe, Canada, and Asia.
• Analysis on key developments in healthcare, personalized medicine, biogreentech, emerging technologies, politics and policy and globalization…and much more.

Individual chapters available for purchase include:

An Industry Evolves   
Top pharmaceutical companies are expected to lose more than $140 billion in annual revenue by 2016. That’s driving an aggressive effort by pharmaceutical companies to fill their pipelines with biotech products, reach into new markets, and find new ways to generate revenue.  

Emerging Technology Drives Personalized Medicine  
A transformation of medicine is underway as new technologies are not only unlocking the genetics underlying disease, but ushering in a new era of personalized medicine.

Combating the Rising Cost of Healthcare   
Pharmaceutical, biotech, and medical device companies are facing a more hostile regulatory and legislative environment as governments seek to reign in healthcare costs. Companies will need to demonstrate their products are not only safe and effective, but provide true economic benefits over existing therapies.

Advancing Toward a Bioeconomy   
Biogreentech companies that survived the global recession are adapting to the challenging environment by broadening their platforms to include renewable chemicals and biopolymers, as well as opportunities in other markets.

Acting Globally   
As the process of globalization proceeds, the world is becoming flat, changing the dynamics of innovation and commercialization as well as the distribution of wealth and the incidence of disease. Any country that is prepared to nurture its venture capital and an entrepreneurial ecosystem is poised to benefit economically and not necessarily at the expense of another region. The chapter includes sections on Canada, Latin America, Europe, Denmark, Hungary, Australia, China, India, Japan, South Korea, Malaysia, The Middle East.

Pharma Reinvents Itself Through M&A and Partnering   
Megadeals marked 2009 starting with Pfizer’s $68 billion acquisition of Wyeth, the merger of Merck and Schering Plough, and Roche’s acquisition of Genentech. Big pharmaceutical companies, at the edge of the patent cliff, were busy becoming biotechs either through acquisitions or partnerships.

A Rough Ride on the Road to Recovery  
The biotech industry closed its books on a year where the industry’s stock values dipped dramatically during a turbulent opening quarter, followed by a slow, steady recovery. The V-shaped stock chart performance of biotech in 2009 mirrored what happened in the general capital markets. Despite the choppiness of the capital markets, three IPOs did get out the door, generating more than $1 billion, raising industry hopes that the IPO window was about to open.